Impact of admission @entity1011 level on clinical outcomes of XXXX with acute @entity583 undergoing primary percutaneous coronary intervention with drug-eluting stent implantation.

@entity1 @entity8 @entity101 @entity66 @entity299 @entity1011 @entity583 @entity715
BACKGROUND: Prognosis of @entity1 with acute @entity583 ( @entity583 ) and @entity8 ( @entity8 ) who received primary percutaneous coronary intervention (PCI) has not been fully investigated in the drug-eluting stent (DES) era. This study aimed to evaluate the impact of admission serum @entity1011 level on short-term outcomes in @entity1 with acute @entity583 undergoing DES-based primary PCI. METHODS: Primary PCI with DES implantation was attempted in 619 consecutive @entity583 @entity1 within 12 hours of symptom onset. Among them, 86 @entity1 had a serum @entity1011 level > or = 115 micromol/L on admission ( @entity8 group), and the remaining 533 @entity1 had normal renal function (non- @entity8 group). The primary endpoint was 30-day major adverse @entity299 (MACE, including death, non-fatal reinfarction, and target vessel revascularization), and the secondary endpoint was subacute stent @entity715 . RESULTS: @entity1 in the @entity8 group were older than those in the non- @entity8 group. There are more female @entity1 in the @entity8 group and they had a history of @entity101 , @entity583 and revascularization. The occurrence rates of Killip class > or = 2 (29.1% vs 18.6%, P = 0.02) and multi-vessel (62.8% vs 44.5%, P = 0.001) and @entity66 (32.6% vs 18.2%, P = 0.002), in-hospital mortality (9.3% vs 3.8%, P = 0.03), and MACE rate during hospitalization (17.4% vs 7.7%, P = 0.006) were higher in the @entity8 group than those in the non- @entity8 group. At a 30-day clinical follow-up, the MACE-free survival rate was significantly reduced in the @entity8 group (76.7% vs 89.9%, P = 0.0003). Angiographic stent @entity715 occurred in 3 (3.5%) and 7 (1.3%) of @entity1 in the @entity8 group and non- @entity8 group, respectively (P = 0.15). Multivariate analysis revealed that the serum @entity1011 level > or = 115 micromol/L on admission was an independent predictor for MACE rate at a 30-day follow-up (Hazard ratio (HR) 3.31, 95% CI 1.19 - 9.18, P < 0.001). CONCLUSION: Despite similar prevalence of stent @entity715 at a 30-day clinical follow-up, the short-term prognosis of @entity583 @entity1 with elevated serum @entity1011 on admission undergoing DES-based primary PCI remains unfavorable.
